Dr Shivakumar Keerthikumar
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
76 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer
DOI: 10.1186/s13046-026-03659-w2026
Journal article
Abstract 2697: Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy response in prostate cancer.
DOI: 10.1158/1538-7445.am2026-26972026
Journal article
Single-Cell Morphomechanics of Prostate Cancer-Associated Fibroblasts Identifies Distinct Features Associated with Patient Outcome
DOI: 10.1002/advs.2025224402025
Journal article
Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology
DOI: 10.1002/1878-0261.700992025
Journal article
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
DOI: 10.1016/j.euf.2025.03.0172025
Journal article
p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer
DOI: 10.1158/1078-0432.CCR-24-38482025
Journal article
PD12-14 NOVEL IMMUNOHISTOCHEMICAL PROFILE TO PREDICT RESPONSE TO INTRAVESICAL BACILLUS CALMETTE–GUÉRIN (BCG) IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
DOI: 10.1097/01.ju.0001109848.08748.9e.14
RECENT SCHOLARLY WORKS
2025
Journal article
Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy.
DOI: 10.1200/jco.2025.43.5_suppl.4202025
Journal article
Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer.
DOI: 10.1200/jco.2025.43.5_suppl.8472024
Journal article
1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
DOI: 10.1016/j.annonc.2024.08.1697